Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.87 |
| ▸ | ACHE | P22303 | 2/20 | 0.87 |
| ▸ | CCR1 | P32246 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13353768 | 0.86 | BCHE (0.66) | BCHEACHECCR1CYP1A2FERMT2 | |
| SCHEMBL2522942 | 0.81 | BCHE (0.70) | BCHEACHECCR1CYP1A2FERMT2 | |
| SCHEMBL12210450 | 0.80 | ACHE (0.57) | BCHEACHECYP1A2 | |
| SCHEMBL13758769 | 0.79 | CCR1 (0.86) | BCHEACHECCR1CYP1A2FERMT2 | |
| SCHEMBL12643220 | 0.79 | CCR1 (0.97) | CCR1CYP1A2FERMT2NR4A2HRH3 | |
| SCHEMBL15481296 | 0.79 | CCR1 (0.97) | CCR1CYP1A2FERMT2NR4A2HRH3 | |
| SCHEMBL17527057 | 0.79 | CCR1 (0.97) | CCR1CYP1A2FERMT2NR4A2HRH3 | |
| SCHEMBL23640948 | 0.78 | CCR1 (0.89) | BCHEACHECCR1CYP1A2FERMT2 | |
| SCHEMBL18163919 | 0.78 | CCR1 (0.89) | BCHEACHECCR1CYP1A2FERMT2 | |
| SCHEMBL15095850 | 0.78 | CYP1A2 (0.55) | BCHEACHECCR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481543-B2 | Compounds for treating parasitic disease | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481543-B2 | Compounds for treating parasitic disease | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110251209-A1 | COMPOUNDS FOR TREATING PARASITIC DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY | 2011-10-13 | — | — | US | disclosed |
| US-20110251209-A1 | COMPOUNDS FOR TREATING PARASITIC DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251209-A1 | COMPOUNDS FOR TREATING PARASITIC DISEASE | EPX, CFTR, TERT | BCHE 493/4885ACHE 1932/4885CCR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.